Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
1 other identifier
observational
52
2 countries
17
Brief Summary
The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component. Other frequent signs include joint, bone and muscle pain, enlarged spleen, liver and lymph nodes, increased blood sedimentation rate (BSR), elevated neutrophil count and abnormalities on bone morphologic investigations. In 2001, the investigators proposed criteria to diagnose this syndrome, which are currently admitted in the literature. The main complications of the Schnitzler syndrome are a difficult-to-control inflammatory anemia, AA-amyloidosis and malignant B lymphoproliferative disorders. About 15% of patients with a Schnitzler will eventually develop a lymphoproliferative disorder; thus this syndrome allows studying the relationship between lymphomagenesis and inflammation. By many aspects, the Schnitzler syndrome is reminiscent of auto-inflammatory syndromes. Though the term auto-inflammatory disease is as to yet restricted to diseases with Mendelian inheritance, some polygenic inflammatory diseases like for example Crohn's disease clearly involve pathogenetic pathways shared with the monogenic auto-inflammatory syndromes. The investigators stipulate that this could also be the case in the Schnitzler syndrome for the following reasons: (1) this is a recurrent fever of unknown cause; (2) the peculiar eruption, characterized pathologically by a neutrophilic infiltrate very similar to the one observed in the auto-inflammatory cryopyrinopathies (CINCA/NOMID syndrome, Muckle-Wells syndrome and familial cold-urticaria); the investigators recently individualized this particular eruption, significantly associated with systemic inflammatory disease, within the group of neutrophilic urticarias (Kieffer et al. Medicine, in press); (3) the occurrence of aseptic neutrophilic osteitis, very similar to the one reported in patients with Majeed syndrome, another auto-inflammatory syndrome; (4) a significant increase of neutrophil count, not otherwise explained; (5) a spectacular response to the IL-1 inhibitor, within hours after the first injection, similar to what is reported in the PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome or the cryopyrinopathies, suggesting a direct pathogenic effect of IL-1.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2009
Longer than P75 for all trials
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2009
CompletedFirst Submitted
Initial submission to the registry
July 3, 2009
CompletedFirst Posted
Study publicly available on registry
July 7, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2017
CompletedSeptember 8, 2017
September 1, 2017
8.2 years
July 3, 2009
September 7, 2017
Conditions
Keywords
Study Arms (2)
A Patients with the Schnitzler syndrome
Patients with the Schnitzler syndrome
B Control subjects:
B1 healthy B2 other diseases
Eligibility Criteria
University hospitals
You may qualify if:
- patients with the Schnitzler syndrome according to criteria established by Lipsker D et al. Medicine (Baltimore) 2001;80:37-44
You may not qualify if:
- children and pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (17)
CHU de Besançon Service de Dermatologie
Besançon, France
Service de DermatologieCHU Morvan5 avenue Foch
Brest, 29609, France
Centre Hospitalier Général Bd Yves du Manoir
Dax, France
Service de Rhumatologie Centre Hospitalier du Mans
Le Mans, 72037, France
Service de Médecine Interne Hôpital Claude-Huriez
Lille, France
Service de DermatologieHôtel Dieu
Lyon, 69288, France
Service médecine interne et thérapeutique Hôpital sainte marguerite
Marseille, 13274, France
Service de Dermatologie Hôpital Saint Eloi 80 avenue A Fliche
Montpellier, 34295, France
Service de dermatologie CHU Hôtel Dieu1 place Alexis Ricordeau
Nantes, 44093, France
Unité de médecine interne Centre Hospitalier G. Renon
Niort, 79021, France
Service d'immuno-hématologie Hôpital St-Louis 1 av Claude Vellefaux
Paris, 75010, France
Service de médecine interne Hôpital Tenon4, rue de la Chine
Paris, 75970, France
Service de dermatologieCHU GUERIN2 rue de la Milétrie
Poitiers, 86021, France
BOYE Thierry
Toulon, 83041, France
Service de médecine interne-néphrologie Centre Hospitalier Valenciennes
Valenciennes, 59322, France
Azienda Ospedaliero Universitaria Policlinico
Bari, 70122, Italy
Clinica DermatologicaUnivesité de GênesVialle Benedetto
Genova, 716132, Italy
Biospecimen
White cells Serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dan Lipsker, Pr
HUS
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2009
First Posted
July 7, 2009
Study Start
July 1, 2009
Primary Completion
September 1, 2017
Study Completion
September 1, 2017
Last Updated
September 8, 2017
Record last verified: 2017-09